PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22644026-2	2012	Lersivirine, a weak inducer of the cytochrome P450 (CYP) enzyme CYP3A4, is metabolized by CYP3A4 and UDP glucuronosyltransferase 2B7 (UGT2B7).	UK 453,061	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-70	
22682979-3	2012	As methadone is metabolized by CYP3A4 and lersivirine is a weak CYP3A4 inducer, it is possible that lersivirine may decrease methadone concentrations.	UK 453,061	42-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-70	
22682979-3	2012	As methadone is metabolized by CYP3A4 and lersivirine is a weak CYP3A4 inducer, it is possible that lersivirine may decrease methadone concentrations.	UK 453,061	100-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37	
22682979-3	2012	As methadone is metabolized by CYP3A4 and lersivirine is a weak CYP3A4 inducer, it is possible that lersivirine may decrease methadone concentrations.	UK 453,061	100-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-70	
22644026-2	2012	Lersivirine, a weak inducer of the cytochrome P450 (CYP) enzyme CYP3A4, is metabolized by CYP3A4 and UDP glucuronosyltransferase 2B7 (UGT2B7).	UK 453,061	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96	
22644026-10	2012	Lersivirine should not be coadministered with rifampin, which is a potent inducer of CYP3A4, UGT2B7, and P-glycoprotein activity and thus substantially lowers lersivirine exposure.	UK 453,061	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-91	
22040521-10	2012	CONCLUSIONS: Inhibition of CYP3A4 and UGT2B7 by ketoconazole increased lersivirine exposure.	UK 453,061	71-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33	
22123705-3	2012	Previous studies have demonstrated that lersivirine is metabolized by glucuronidation via UGT2B7 and by cytochrome P450 3A4 (CYP3A4).	UK 453,061	40-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	104-123	
22123705-3	2012	Previous studies have demonstrated that lersivirine is metabolized by glucuronidation via UGT2B7 and by cytochrome P450 3A4 (CYP3A4).	UK 453,061	40-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-131	
22123705-4	2012	Lersivirine is also a weak inducer of the CYP3A4 enzyme.	UK 453,061	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48	
22123705-5	2012	Therefore, coadministered lersivirine could potentially affect the pharmacokinetics of maraviroc, a CCR5 antagonist metabolized by CYP3A4, and raltegravir, an integrase inhibitor metabolized by glucuronidation.	UK 453,061	26-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-137	
20124396-9	2010	In vitro studies showed that UGT2B7 and CYP3A4 are responsible for the majority of lersivirine metabolism in humans.	UK 453,061	83-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46